NCT04744584Completed
Medication Reconciliation in Pulmonary Hypertension
Optimizing Drug Management of Patients Suffering From Rare Disease Through Medication Reconciliation: Proof of Concept in Pulmonary Hypertension
Source: ClinicalTrials.gov · Last updated 16 Jul 2024
Brief summary (registry, in English)
Pulmonary hypertension (PH) is a life threatening condition. In PH, pulmonary arterial hypertension (PAH) and chronic thrombo-embolic chronic pulmonary hypertension (CTEPH) are two rare diseases requiring specific and complex drug management. In France ,a part of these treatments ,only available in hospital pharmacies, are generally unknown from community health care professionals despite the high risk of drug-interactions and side effects. Anticipating medication errors at the begging of the disease is therefore important, and could be done through medication reconciliation.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 129 (actual)
- First submitted
- 15 Jan 2021
- Start date
- 16 Feb 2021
- Primary completion date
- 15 Jun 2024
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- NCT number
- NCT04744584
What you commit to
- Study type: Observational
- Participants enrolled: 129
- From 16 Feb 2021 to the primary completion date, 15 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient on transplant list
Other illness
- Inability to give information to the patient either due to language barrier or to cognitive impairment
Other
- Patient suffering from another form of PH
- Patient under guardianship or curator
- Patient hosted in institution on discharge from hospital (follow-up care and long-term rehabilitation)
- Patient with a life expectancy of less than 1 year
- Patient refusal
- Length of stay \< 48 hours
Who the study is looking for
- Patient affiliated or entitled to a social security scheme
- At least 18 years old
- Patient with enlightened information of the study and not opposed with it.
- For patient without MR: patient hospitalized for the first re-evaluation of PAH or CTEPH within 12 months following the first assessment hospitalization (ie: first right heart catheterization at bicetre Hospital).
- For patient with MR: patient hospitalized for first assessment (first right heart catheterization at bicetre Hospital) of PAH or CTEPH
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital BICETRE Coordinator of this site? Confirm its status | Le Kremlin-Bicêtre | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.